GALD Share Price Performance
CHF 0
-77.50 (-100.00%)
Price CHF 0
Fair ValueCHF 182.39
Share Pricen/a
Galderma Group AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
GALD Community Narratives
AN
Fair Value CHF 182.39 16.3% undervalued intrinsic discount
GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value CHF 120.62 26.6% overvalued intrinsic discount
Rising Global Controls And Biosimilar Risks Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CHF 192.12 20.5% undervalued intrinsic discount
Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Global Controls And Biosimilar Risks Will Squeeze Margins
Key Takeaways Heightened regulatory scrutiny, emerging generics, and shifting consumer preferences threaten profitability, market share, and require costly adaptation of Galderma's product portfolio. Macroeconomic headwinds and complex, costly R&D cycles put pressure on revenue growth, innovation leadership, and overall financial returns.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 120.62
26.6% overvalued intrinsic discount
Fair Value
Revenue
16.32% p.a.
Profit Margin
16.45%
Future PE
28.88x
Price in 2029
CHF 134.82
GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside
Key Takeaways Accelerated growth and profitability are driven by innovative, premium products, digital engagement, and expanding presence in emerging markets. Strategic R&D investments and partnerships enhance Galderma's ability to capture rising demand for advanced dermatological and aesthetic solutions.Read more
123
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
CHF 182.39
16.3% undervalued intrinsic discount
Fair Value
Revenue
16.89% p.a.
Profit Margin
19.52%
Future PE
35.56x
Price in 2029
CHF 203.85
Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics
Key Takeaways Nemluvio and Galderma's innovation pipeline could drive much stronger earnings growth and margin expansion than currently anticipated by the market. Execution in premium product segments and underpenetrated markets positions Galderma for significant, sustained gains in global revenue and market share.Read more
32
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 192.12
20.5% undervalued intrinsic discount
Fair Value
Revenue
22.02% p.a.
Profit Margin
21.97%
Future PE
35.32x
Price in 2029
CHF 214.81
Trending Discussion
Recently Updated Narratives
AN
GALD: Elevated Expectations For Dermatology Franchise Will Likely Cap Future Share Upside
Fair Value: CHF 120.62 26.6% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Execution Risk
Fair Value: CHF 182.39 16.3% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GALD: Higher CHF 195 Outlook Will Support Future Re Rating Conviction
Fair Value: CHF 192.12 20.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Galderma Group AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 23, 2026
- 2.61
- 68.86%
- 11.70%
- 32.0%
About GALD
- Founded
- 1981
- Employees
- 7676
- CEO
- WebsiteView website
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
